Clinical Validation of PROPECG-TMT

Clinical Validation of PROPECG-TMT: Evaluation of Ability of the Artificial Intelligence Model, PROPECG-TMT, to Improve Physician's in Screening Patients Who Needs Coronary Artery Revascularization Based on TMT-ECG.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06624852

Enrollment

100

Registered

2024-10-03

Start date

2023-02-13

Completion date

2024-02-13

Last updated

2024-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

This clinical validation evaluates the performances of physicians with and without learning with PROPECG-TMT assistance for screening coronary artery revascularization on TMT-ECG. There are two endpoints used to evaluate performances: Accuracy (primary endpoints with pair specificity/sensitivity, and PPV/NPV), and time needed for screening (secondary endpoints with time measurements in all cases).

Interventions

OTHERScreening for coronary artery revascularization based on TMT-ECG

Screening for coronary artery revascularization based on TMT-ECG with and without the assistance of PROPECG-TMT

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* TMT ECG exams adjudicated as equivocal cases

Exclusion criteria

* Exams not converting to median beat ECG * Exams not containing interpretable exercise

Design outcomes

Primary

Measure	Time frame	Description
measurement of screening performances	1 month	calculation of sensitivity, specificity, NPV, PPV

Secondary

Measure	Time frame	Description
Time needed for screening all cases	1 month	measurement of the time and comparison between the two cohorts

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026